Internatl. Pharmaceutical Products
Executive Summary
Company announced an exclusive U.S./Canada licensing agreement with the Italian firm Laboratorios Cusi, covering manufacture and distribution of timolol maleate for treatment of glaucoma. Merck currently sells the beta blocker in the U.S. under the brand name Timoptic. U.S. sales are estimated at $130 mil. per year.